74,600 Shares in Olema Pharmaceuticals, Inc. $OLMA Purchased by Swiss National Bank

Swiss National Bank bought a new stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 74,600 shares of the company’s stock, valued at approximately $1,112,000. Swiss National Bank owned 0.09% of Olema Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Siren L.L.C. bought a new position in Olema Pharmaceuticals in the 4th quarter worth approximately $82,518,000. Janus Henderson Group PLC boosted its position in shares of Olema Pharmaceuticals by 87.1% in the fourth quarter. Janus Henderson Group PLC now owns 6,710,194 shares of the company’s stock valued at $167,901,000 after acquiring an additional 3,124,345 shares during the period. Cormorant Asset Management LP bought a new stake in shares of Olema Pharmaceuticals in the fourth quarter valued at approximately $68,750,000. RA Capital Management L.P. acquired a new stake in shares of Olema Pharmaceuticals in the fourth quarter worth $65,000,000. Finally, Bain Capital Life Sciences Investors LLC grew its stake in shares of Olema Pharmaceuticals by 24.3% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock worth $212,716,000 after acquiring an additional 1,664,687 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on OLMA shares. HC Wainwright reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research note on Friday, May 22nd. Wall Street Zen downgraded shares of Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, July 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Friday, July 17th. Finally, Guggenheim dropped their price objective on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $44.10.

Insider Transactions at Olema Pharmaceuticals

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 12,500 shares of the company’s stock in a transaction on Thursday, July 23rd. The stock was sold at an average price of $11.58, for a total transaction of $144,750.00. Following the transaction, the director owned 715,270 shares of the company’s stock, valued at approximately $8,282,826.60. This represents a 1.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 12.56% of the company’s stock.

Olema Pharmaceuticals Trading Down 3.1%

Shares of NASDAQ OLMA opened at $11.45 on Friday. Olema Pharmaceuticals, Inc. has a 1-year low of $4.47 and a 1-year high of $36.26. The company has a 50-day moving average of $11.42 and a two-hundred day moving average of $16.54. The company has a market cap of $1.00 billion, a PE ratio of -5.67 and a beta of 2.00. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, meeting the consensus estimate of ($0.52). As a group, equities analysts expect that Olema Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.